Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Juri Alessandro Giannotta"'
Autor:
Marco Capecchi, Giada Gazzola, Pasquale Agosti, Pasqualina De Leo, Ilaria Mancini, Barbara Ferrari, Juri Alessandro Giannotta, Andrea Artoni, Flora Peyvandi
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Externí odkaz:
https://doaj.org/article/894f8a576227424bb98fd6c34802e735
Autor:
Bruno Fattizzo, Valentina Carrai, Monica Crugnola, Erminia Baldacci, Marta Bellini, Costanza Bosi, Elisa Buzzatti, Domenica Caramazza, Giuseppe Carli, Monica Carpenedo, Cristina Clissa, Cristina Danesin, Maria Rosaria De Paolis, Juri Alessandro Giannotta, Vanessa Innao, Monia Marchetti, Uros Markovic, Alessandro Morotti, Mariasanta Napolitano, Andrea Patriarca, Loredana Pettine, Antonella Poloni, Elena Rivolti, Elena Rossi, Teresa Maria Santeremo, Cristina Santoro, Maria Elena Zannier, Francesco Zaja, Silvia Cantoni, Francesca Palandri, Valerio De Stefano
Publikováno v:
HemaSphere, Vol 7, p e024400a (2023)
Externí odkaz:
https://doaj.org/article/a80eb4b9d83b4b959bc96aa6ee514995
Autor:
Bruno Fattizzo, Marta Bortolotti, Juri Alessandro Giannotta, Dario Consonni, Silvia Cantoni, Wilma Barcellini
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Data concerning the efficacy of SARS-CoV-2 vaccines in patients with non-oncological hematologic conditions are lacking. These include autoimmune cytopenias (autoimmune hemolytic anemia AIHA, immune thrombocytopenia ITP, and autoimmune neutr
Externí odkaz:
https://doaj.org/article/2b55b1fe968642a4b24c55d41836ee30
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Abstract Congenital hemolytic anemias (CHAs) comprise defects of the erythrocyte membrane proteins and of red blood cell enzymes metabolism, along with alterations of erythropoiesis. These rare and heterogeneous conditions may generate several diffic
Externí odkaz:
https://doaj.org/article/5ab92eba01744aee8d72c30447593e5e
Autor:
Bruno Fattizzo, Marta Bortolotti, Nicolò Rampi, Francesca Cavallaro, Juri Alessandro Giannotta, Cristina Bucelli, Ramona Cassin, Matteo Claudio Da Vià, Giulia Galassi, Alessandro Noto, Loredana Pettine, Francesca Gaia Rossi, Mariarita Sciumè, Ferruccio Ceriotti, Dario Consonni, Wilma Barcellini, Luca Baldini
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Hematologic patients show lower responses to SARS-CoV-2 vaccines, but predictors of seroconversion are lacking. In this prospective cohort study, hematologic patients undergoing SARS-CoV-2 mRNA vaccination at a single center in Milan, Italy, were sam
Externí odkaz:
https://doaj.org/article/797f5cc69ba94d6bb79dcbaf05eda072
Autor:
Bruno Fattizzo, Silvia Cantoni, Juri Alessandro Giannotta, Laura Bandiera, Rachele Zavaglia, Marta Bortolotti, Wilma Barcellini
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) show good responses to frontline steroids. About two-third of cases relapse and require second-line treatment, including rituximab, mainly effective in AIHA, and thrombo
Externí odkaz:
https://doaj.org/article/05bf325446464621941860a999d758a7
Autor:
Bruno Fattizzo, Giorgia Virginia Levati, Juri Alessandro Giannotta, Giulio Cassanello, Lilla Marcella Cro, Anna Zaninoni, Marzia Barbieri, Giorgio Alberto Croci, Nicoletta Revelli, Wilma Barcellini
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies are still limited and mainly consist of erythropoiesis-stimulating agents (ESAs) and transfusi
Externí odkaz:
https://doaj.org/article/d5f012f1e2de4ebc9563150edf185ee7
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolytic anemia and thrombosis and is notoriously associated with aplastic anemia and myelodysplastic syndromes. Rarer associations include myeloproliferative neoplasms (MPN
Externí odkaz:
https://doaj.org/article/2bd01cf112534f479256db26ca43b4a0
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma cells and lymphocytes
Externí odkaz:
https://doaj.org/article/05583e8797654fc48edb971217a231d8
Autor:
Bruno Fattizzo, Valentina Bellani, Raffaella Pasquale, Juri Alessandro Giannotta, Wilma Barcellini
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Large granular lymphocytes (LGL) are lymphoid cells characterized by either a T-cell or a natural killer phenotype whose expansion may be reactive to toxic, infectious, and neoplastic conditions, or result from clonal selection. Recently, the higher
Externí odkaz:
https://doaj.org/article/aab96f3a748546e3849bc9e0039e9b6a